Physician profile
Hamza D Bhatti
NPI 1043598352
$39,947.33
in general payments reported to CMS, 2019-2025
28 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $281 · 2021: $390 · 2022: $1,524 · 2023: $3,791 · 2024: $20K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $7,209 · Consulting Fee: $2,975 · Travel and Lodging: $2,858 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,182.50 |
| Food and Beverage | $7,208.88 |
| Consulting Fee | $2,975.00 |
| Travel and Lodging | $2,857.78 |
| Education | $294.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31,454.75 | 2021-2025 | Libtayo, Dupixent |
| Incyte Corporation | $1,246.16 | 2021-2025 | Opzelura |
| Amgen INC. | $997.22 | 2021-2024 | Otezla |
| Genzyme Corporation | $944.20 | 2020-2025 | |
| Abbvie INC. | $848.67 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $765.20 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $628.76 | 2022-2024 | Sotyktu |
| Biofrontera INC. | $421.80 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $418.53 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $312.72 | 2020-2023 | Jublia |
| Galderma Laboratories, L.P. | $281.24 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $270.35 | 2020-2025 | |
| Leo Pharma INC. | $243.65 | 2021-2025 | Adbry |
| Pfizer INC. | $237.00 | 2023-2024 | |
| Dermavant Sciences, INC. | $191.94 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $172.34 | 2021-2023 | Klisyri |
| Organogenesis INC. | $94.44 | 2023-2025 | Puraply, Affinity, Puraply Wound Matrix |
| Sun Pharmaceutical Industries INC. | $83.16 | 2023-2025 | Absorica Ld, Winlevi, Ilumya |
| Merz North America, INC. | $64.67 | 2023 | Xeomin |
| Biowound Solutions, INC. | $47.71 | 2025 | Bio-Connekt |
| Allergan, INC. | $45.47 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $42.56 | 2024 | Ycanth |
| Ucb, INC. | $37.60 | 2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $28.66 | 2020-2021 | |
| Mimedx Group, INC. | $25.42 | 2024 | |
| Epi Health, LLC | $14.91 | 2022 | |
| Journey Medical Corporation | $14.29 | 2024 | |
| Strata Skin Sciences, INC. | $13.91 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.